Loading the chart…
| Outcome | Chance | 24h | 1 week | Bid · Ask | 24h volume | Ends |
|---|---|---|---|---|---|---|
| December 31, 2026 | 41% | −10 pts | −11 pts | 17¢ · 64¢ (47¢) | $5 | in 68d |
No trades of $1,000 or more lately.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Sources: Polymarket's Gamma API, its CLOB price history and its Data API, read every two minutes. Prices are each outcome's Yes price, which is the market's probability: 41¢ for December 31, 2026 means the market gives it about 41%.